Shots:
- The company has completed the enrollment in the first cohort of P- I/II trial involves assessing AMT-130 in 10 patients, out of which six patients received treatment with AMT-130 and four patients received imitation surgery for early manifest HD
- The company plans to initiate a second clinical study of AMT-130 in the EU in H2’21 while the enrollment of the second dose cohort is expected to initiate in Q3’21
- The company also plans to initiate an open-label trial of AMT-130 in the EU later this year. The study will enroll 15 patients with early manifest HD across two dose cohorts
Click here to read full press release/ article | Ref: PRNewswire | Image: Stat News
The post uniQure Reports Completion of Enrollment in First Cohort of P- I/II Trial for AMT-130 to Treat Huntington’s Disease first appeared on PharmaShots.
